The effect of zoledronate and pamidronate on the intestinal permeability barrier in vitro and in vivo

International Journal of Pharmaceutics

Volumn 153, Issue 1, 1997, Pages 59-66

  Green, Jonathan R ^a   Clay, Val ^b   Richardson, Joanne ^b   Hassan, Ian F ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Novartis Pharmaceuticals Ltd   (United Kingdom)

Author keywords

Bisphosphonate; Caco 2; Intestine; Pamidronate; Tolerability; Zoledronate

Indexed keywords

PAMIDRONIC ACID; ZOLEDRONIC ACID;

ANIMAL EXPERIMENT; ARTICLE; CELL STRAIN CACO 2; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG TOLERABILITY; HUMAN; HUMAN CELL; INTESTINE INJURY; INTESTINE MUCOSA PERMEABILITY; MALE; NONHUMAN; OSTEOLYSIS; PERMEABILITY BARRIER; PRIORITY JOURNAL; RAT; TIGHT JUNCTION;

EID: 0030844652     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(97)00094-X     Document Type: Article

References (25)

1. Artursson, P., 1990. Epithelial transport of drugs in cell culture. I: A model for studying the passive diffusion of drugs over intestinal absorbtive (Caco-2) cells. J. Pharm. Sci. 79, 476-482.
2. Artursson, P., Magnusson, C., 1990. Epithelial transport of drugs in cell culture. II: Effect of extracellular calcium concentration on the paracellular transport of drugs of different lipophilicities across monolayers of intestinal epithelial (Caco-2) cells. J. Pharm. Sci. 79, 595-600.
3. Berenson, J.R., Lichtenstein, A., Porter, L. et al., 1996. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. New Engl. J. Med. 334, 488-493.
4. Bisaz, S., Jung, A., Fleisch, H., 1978. Uptake by bone of pyrophosphate, diphosphonates and their technetium derivatives. Clin. Sci. Mol. Med. 54, 265-272.
5. Boulenc, X., Roques, C., Joyeux, H., Berger, Y., Fabre, G., 1995. Bisphosphonates increase tight junction permeability in the human intestinal epithelial (Caco-2) model. Int. J. Pharm. 123, 13-24.
6. Cassidy, M.M., Tidball, C.S., 1967. Cellular mechanism of intestinal permeability alterations produced by chelation depletion. J. Cell Biol., 32, 685-698.
7. De Groen, P.C., Lubbe, D.F., Hirsch, L.J. et al., 1996. Esophagitis associated with the use of alendronate. New Engl. J. Med., 335, 1016-1021.
8. Dubois, A., van Eerdewegh, P., Gardner, J.D., 1977. Gastric emptying and secretion in Zollinger-Ellison Syndrome. J. Clin. Invest. 59, 255-263.
9. Fleisch, H., 1995. Bisphosphonates in bone disease: from the laboratory to the patient, Parthenon Publishing Group Ltd., New York and London.
10. Fogh, J., Wright, W.C., Loveless, J.D., 1977. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J. Natl. Cancer Inst. 58, 209-214.
11. Grabenstetter, R.J., Cilley, W.A., 1971. Polynuclear complex formation in solutions of calcium ion and ethane-1-hydroxy-1,1-diphosphonic acid. I. Complexometric and pH titrations. J. Phys. Chem. 75, 676-682.
12. Green, J.R., Müller, K., Jaeggi, K.A., 1994. Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J. Bone Miner. Res. 9, 745-751.
13. Gural, R.P., Chungi, V.S., Shrewsbury, R.P., Dittert, L.W., 1985. Dose-dependent absorption of disodium etidronate. J. Pharm. Pharmacol. 37, 443-445.
14. Hamilton, I., Rothwell, J., Archer, D., Axon, A.T.R., 1987. Permeability of the rat small intestine to carbohydrate probe molecules. Clin. Sci. 73, 189-196.
15. Hilgers, A.R., Conradi, R.A., Burton, P.S., 1990. Caco-2 cell monolayers as a model for drug transport across the intestinal mucosa. Pharm. Res. 7, 902-910.
16. Lufkin, E.G., Argueta, R., Whitaker, M.D. et al., 1994. Pamidronate: an unrecognized problem in gastrointestinal tolerability. Osteoporosis Int. 4, 320-322.
17. Nadai, T., Kondo, R., Tatematsu, A., Sezaki, H., 1972. Drug-induced histological changes and its consequences on the permeability of the small intestinal mucosa. I. EDTA, tetracycline, and sodium laurylsulfate. Chem. Pharm. Bull. 29, 1139-1144.
18. Nicklin, P.L., Irwin, W.J., Hassan, I.F., Mackay, M., 1995. Development of a minimum-calcium Caco-2 monolayer model: calcium and magnesium ions retard the transport of pamidronate. Int. J. Pharm. 123, 187-197.
19. Schanker, L.S., Johnson, J.M., 1961. Increased intestinal absorption of foreign organic compounds in the presence of ethylenediaminetetraacetate (EDTA). Biochem. Pharmacol. 8, 421-422.
20. Shrewsbury, R.P., Metcalf, T.B., Weiss, D.L., Dittert, L.W., 1982. Influence of disodium etidronate on salicylic acid absorption in the rat. J. Pharm. Pharmacol. 34, 823-825.
21. Twiss, I.M., de Water, R., den Hartigh, J. et al., 1994. Cytotoxic effects of pamidronate on monolayers of human intestinal epithelial (Caco-2) cells and its epithelial transport. J. Pharm. Sci., 83, 699-703.
22. Van Hoogdalem, E.J., Wackwitz, A.T.E., de Boer, A.G., Breimer, D.D., 1989. 3-Amino-1-hydroxypropylidene-1,1-diphosphonate (APD): a novel enhancer of rectal cefoxitin absorption in rats. J. Pharm. Pharmacol. 41, 339-341.
23. Wiers, B.H., 1971. Polynuclear complex formation in solutions of calcium ion and ethane-1-hydroxy-1,1-diphosphonic acid. II. Light scattering, sedimentation, mobility, and dialysis measurements. J. Phys. Chem. 75, 682-687.
24. Wilson, G., Hassan, I.F., Dix, C.J., Williamson, I., Shah, R., Mackay, M., 1990. Transport and permeability properties of human Caco-2 cells: an in vitro model of the intestinal epithelial cell barrier. J. Control. Rel. 11, 25-40.
25. Windsor, E., Cronheim, G., 1961. Gastro-intestinal absorption of heparin and synthetic heparinoids. Nature 190, 263-264.